A Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

被引：5

作者：

Smith, Stephen D. ^{[1
]}

Starodub, Alexander ^{[2
]}

Stevens, Don A. ^{[3
]}

Shastri, Aditi ^{[4
]}

Porcu, Pierluigi ^{[5
]}

Feldman, Tatyana ^{[6
]}

Ewesuedo, Reggie ^{[7
]}

DeSavi, Chris ^{[7
]}

Dey, Joyoti ^{[7
]}

Agarwal, Sagar ^{[7
]}

Donohue, Sean ^{[7
]}

Perea, Rachelle ^{[7
]}

Klaus, Christine ^{[7
]}

Gollob, Jared ^{[7
]}

机构：

[1] Univ Washington, Fred Hutchinson Canc Ctr, Div Med Oncol, Seattle, WA 98195 USA

[2] Christ Hosp, Cincinnati, OH 45219 USA

[3] Norton Canc Inst, Norton Healthcare, Louisville, KY USA

[4] Albert Einstein Coll Med, Montefiore Med Ctr, Oncol, Hematol Oncol, Bronx, NY 10467 USA

[5] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr Jefferson Hlth, Philadelphia, PA 19107 USA

[6] Hackensack Univ, HackensackMeridianHlth Sch Med, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA

[7] Kymera Therapeut, Watertown, MA USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-169514

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：12024 / 12025

页数：2

共 50 条

[21] Phase I study of rituximab and CAMPATH-1H in patients with relapsed or refractory chronic lymphocytic leukemia.
Nabhan, C
Tallman, MS
Riley, MB
Fitzpatrick, J
Gordon, LI
Gartenhaus, R
Kuzel, T
Siegel, R
Rosen, ST
BLOOD, 2001, 98 (11) : 365A - 365A
[22] Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia
Byrd, John C.
Kipps, Thomas J.
Flinn, Ian W.
Castro, Januaro
Lin, Thomas S.
Wierda, William
Heerema, Nyla
Woodworth, James
Hughes, Steve
Tangri, Shabnam
Harris, Sarah
Wynne, Dee
Molina, Arturo
Leigh, Bryan
O'Brien, Susan
BLOOD, 2010, 115 (03) : 489 - 495
[23] Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
Annunziata, Christina M.
Kohn, Elise C.
LoRusso, Patricia
Houston, Nicole D.
Coleman, Robert L.
Buzoianu, Manuela
Robbie, Gabriel
Lechleider, Robert
INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 77 - 84
[24] Phase 1 study of ABBV-155 ± paclitaxel in relapsed/ refractory solid tumors: Results in Japanese patients
Shimizu, Toshio
Yonemori, Kan
Kuboki, Yasutoshi
Tolcher, Anthony
Kurokawa, Misaki
Munasinghe, Wijith
Phillips, Andrew
Souers, Andrew
Johnson, Eric
He, Lei
Weitzman, Aaron
Powderly, John
Lorusso, Patricia
Naito, Yoichi
ANNALS OF ONCOLOGY, 2023, 34 : S1420 - S1420
[25] Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
Christina M. Annunziata
Elise C. Kohn
Patricia LoRusso
Nicole D. Houston
Robert L. Coleman
Manuela Buzoianu
Gabriel Robbie
Robert Lechleider
Investigational New Drugs, 2013, 31 : 77 - 84
[26] A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors
Cash, Thomas
Jonus, Hunter C.
Tsvetkova, Maya
Beumer, Jan H.
Sadanand, Arhanti
Lee, Jasmine Y. Y.
Henry, Curtis J.
Aguilera, Dolly
Harvey, R. Donald
Goldsmith, Kelly C.
PEDIATRIC BLOOD & CANCER, 2023, 70 (08)
[27] Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
Oh, Do-Youn
Lee, Se-Hoon
Han, Sae-Won
Kim, Mi-Jung
Kim, Tae-Min
Kim, Tae-You
Heo, Dae Seog
Yuasa, Miyuki
Yanagihara, Yasuo
Bang, Yung-Jue
CANCER RESEARCH AND TREATMENT, 2015, 47 (04): : 607 - 615
[28] Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
Izutsu, Koji
Yamamoto, Kazuhito
Kato, Koji
Ishikawa, Takayuki
Fukuhara, Noriko
Terui, Yasuhito
Choi, Ilseung
Humphrey, Kathryn
Kim, Su Young
Okubo, Sumiko
Ogawa, Natsumi
Nishimura, Yasuko
Salem, Ahmed Hamed
Maruyama, Dai
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (03) : 370 - 380
[29] Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
Koji Izutsu
Kazuhito Yamamoto
Koji Kato
Takayuki Ishikawa
Noriko Fukuhara
Yasuhito Terui
Ilseung Choi
Kathryn Humphrey
Su Young Kim
Sumiko Okubo
Natsumi Ogawa
Yasuko Nishimura
Ahmed Hamed Salem
Dai Maruyama
International Journal of Hematology, 2021, 113 : 370 - 380
[30] VENETOCLAX IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY SOLID TUMORS: UPDATED FINDINGS FROM A PHASE 1 STUDY
Morgenstern, Daniel
Khaw, Seong
Gerber, Nicolas
Place, Andrew
Corradini, Nadege
Loh, Mignon
Verschuur, Arnauld
Ziegler, David
Fraser, Chris
Cooper, Todd
Forlenza, Christopher
O'Brien, Maureen
Federico, Sara
Van Eijkelenburg, Natasha
Onishi, Maika
Unnebrink, Kristina
Chen, Xin
Badawi, Mohamed
Ghanim, Majd
Palenski, Tammy
Goldsmith, Kelly
PEDIATRIC BLOOD & CANCER, 2022, 69

← 1 2 3 4 5 →